KRSA
Korsana Biosciences Inc.
KRSA | NASDAQ
$30.43
+$0.29 (+0.96%)
Nov 2, 2026, 9:49 AM ET · Market open
+0.96%
(1D)No price chart data available for 1D timeframe.
Rating
43.5
-2.0 ptsFundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #437/1028 (Top 43%)
Key Statistics
Market Data
Market Cap $142.48M
1D Range
29.82 30.44
52W Range
7.56 44.66
Valuation (TTM)
PE -2.50
PB 27.74
EV/EBITDA -20.83
Valuation (NTM)
Forward PE N/A
Forward PEG 0.04
Price Target $53.00
Cash Flow
FCF Yield -3.1%
SBC Adj. FCF Yield -3.3%
SBC Impact -5.1%
Margins
Gross Margin 61.6%
Operating Margin -359.2%
FCF Margin -234.3%
Growth (CAGR)
Revenue 3Y | 5Y 70.0% |
-12.0%
Dil EPS 3Y | 5Y 68.0% |
62.9%
FCF 3Y | 5Y 56.1% |
55.5%
Returns
ROA -96.8%
ROE -88.0%
ROIC -134.2%
Financial Health
Net Cash
$1.39M
Current Ratio 0.82
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes seve...
Sector Healthcare
Industry Biotechnology
Employees 19
IPO Date Sep 9, 2026
Website korsana.com
Fiscal Year January - December
Latest News
2 months ago · globenewswire.com
Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 MillionAdvancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in Alzheimer's patients anticipated by year-end 2027 or first quarter of 2028
Add to Watchlist
Select watchlists to add or remove KRSA